welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!
view full news & meetings section

Tucson pharmaceutical company sells exclusive option for cancer drug in deal worth up to $190 million


Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.

https://www.fapvoice.com/wp-content/uploads/2016/04/12.jpg

expertly curated content related to this topic

en English
en Englishpt Portuguesees Spanish

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close